Penumbra price to sales ratio PEN

Market value divided by revenue over the last twelve months, since 2016.

Today, Oct 23, 2026: 8.5×
10-year median: 10.3×
Against its 10-year history: 22nd; percentile: 0 is its lowest day, 100 its highest
10-year range: 5.8× to 19.9×
Peer median: 3.4×

Penumbra's price to sales ratio is 8.5× as of Oct 23, 2026.

That is below its ten-year median of 10.3×, lower than on 78% of days in the last ten years.

Over that time it ranged from 5.8× in Jun 2022 to 19.9× in Apr 2021.

The median for 10 medical instruments and supplies stocks of a similar size is 3.4×.

Price to sales ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	8.5×	8.3×	10.5×
2025	9.3×	6.9×	9.4×
2024	7.9×	5.8×	10.6×
2023	9.8×	7.0×	14.9×
2022	10.2×	5.8×	13.4×
2021	15.1×	12.5×	19.9×
2020	11.8×	8.5×	17.9×
2019	11.0×	9.3×	13.3×
2018	10.2×	9.3×	15.6×
2017	10.3×	8.8×	11.6×
2016	8.3×	6.9×	10.5×

Against its peers

Companies in Medical - Instruments & Supplies nearest Penumbra's size, closest first, today.

Company	Price to sales ratio
PENPenumbra	8.5×
COOCooper Companies	2.7×
SOLVSolventum	1.7×
ALGNAlign Technology	2.7×
GMEDGlobus Medical	3.5×
PODDInsulet	3.4×
MSAMSA Safety	3.6×
WSTWest Pharmaceutical Services	8.3×
MMSIMerit Medical Systems	3.5×
HAEHaemonetics	4.0×
VNTVontier	1.5×
Peer median	3.4×

What the price to sales ratio tells you

Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.

Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.

More on Penumbra

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.